InDex Pharmaceuticals Holding AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INDEX.ST research report →
Companywww.indexpharma.com
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases.
- CEO
- Jenny Sundqvist
- IPO
- 2016
- Employees
- 4
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $3.69B
- P/E
- -3.41
- P/S
- -92.15
- P/B
- 0.53
- EV/EBITDA
- -2.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 192.98%
- Op Margin
- 2733.06%
- Net Margin
- 2345.04%
- ROE
- -15.05%
- ROIC
- -17.99%
Growth & Income
- Revenue
- $97.50M · 8408.29%
- Net Income
- $-95,265,000 · 2.23%
- EPS
- $-0.18 · 0.00%
- Op Income
- $-95,708,000
- FCF YoY
- 70.66%
Performance & Tape
- 52W High
- $0.93
- 52W Low
- $0.20
- 50D MA
- $0.41
- 200D MA
- $0.45
- Beta
- -0.21
- Avg Volume
- 5.19M
Get TickerSpark's AI analysis on INDEX.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our INDEX.ST Coverage
We haven't published any research on INDEX.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INDEX.ST Report →